Topics:
ARS 2014|Breast Cancer|Colorectal Cancer|Leukemia & Lymphoma|Lung Cancer|Melanoma|ASCO 2014|Prostate Cancer|Browse All Topics

Prostate Cancer

Neuroendocrine (Small-Cell) Carcinomas: Why They Teach Us Essential Lessons About Prostate Cancer

Aggressive variants of prostate cancer often take the form of neuroendocrine or small-cell carcinomas, which frequently lack androgen receptor expression and respond poorly to hormonal therapies.

Prostate Cancer

Decision-Making in the Management of Early Prostate Cancer

John L. Gore, MD
March 02, 2015 | ASCO 2015 Genitourinary Cancers Symposium, Prostate Cancer
By

As part of our coverage of the ASCO GU Cancers Symposium, we discuss decision-making in the management of patients with early-stage prostate cancer.

Two Clinical Factors May Predict PSA Response to Cabazitaxel

Anna Azvolinsky, PhD
News | March 02, 2015 | ASCO 2015 Genitourinary Cancers Symposium, Genitourinary Cancers, Prostate Cancer
By

Two clinical factors may predict PSA response to cabazitaxel in men with metastatic castration-resistant prostate cancer.

Study Confirms 4Kscore Accurately Predicts High-Grade Prostate Cancer

Anna Azvolinsky, PhD
News | March 02, 2015 | ASCO 2015 Genitourinary Cancers Symposium, Genitourinary Cancers, Prostate Cancer
By

The 4Kscore blood test has been shown to accurately detect the presence of high-grade prostate cancer, according to a study presented at ASCO GU.

Surveillance Risky in Intermediate-Risk Prostate Cancer?

Anna Azvolinsky, PhD
News | February 27, 2015 | ASCO 2015 Genitourinary Cancers Symposium, Genitourinary Cancers, Prostate Cancer
By

Intermediate-risk prostate cancer patients managed with surveillance had worse outcomes compared with low-risk prostate cancer patients managed with surveillance.

High-Dose Radiotherapy Fails to Improve Prostate Cancer Survival

Anna Azvolinsky, PhD
News | February 27, 2015 | ASCO 2015 Genitourinary Cancers Symposium, Genitourinary Cancers, Prostate Cancer
By

High-dose radiation therapy did not improve overall survival compared with the standard dose in stage II localized prostate cancer, but did show some benefits.

Higher-Risk Prostate Cancer on the Rise?

Anna Azvolinsky, PhD
News | February 24, 2015 | ASCO 2015 Genitourinary Cancers Symposium, Genitourinary Cancers, Prostate Cancer
By

A large retrospective analysis suggests the number of patients diagnosed with intermediate- and high-risk prostate cancer has increased since 2011.

Increased Risk of Aggressive Prostate Cancer in Testicular Cancer Survivors

Leah Lawrence
News | February 23, 2015 | ASCO 2015 Genitourinary Cancers Symposium, Genitourinary Cancers, Prostate Cancer, Testicular Cancer
By

Patients with a history of testicular cancer had a fivefold higher risk of developing aggressive prostate cancer when compared with those with no history of testicular cancer.

Pages

Subscribe to Prostate Cancer on [sitename]
View More Videos
View More Slideshows

By clicking Accept, you agree to become a member of the UBM Medica Community.